A detailed history of Elkhorn Partners Limited Partnership transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Elkhorn Partners Limited Partnership holds 5,650 shares of GILD stock, worth $498,838. This represents 0.27% of its overall portfolio holdings.

Number of Shares
5,650
Previous 950 494.74%
Holding current value
$498,838
Previous $70,000 454.29%
% of portfolio
0.27%
Previous 0.05%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$63.15 - $72.88 $296,805 - $342,536
4,700 Added 494.74%
5,650 $388,000
Q1 2024

May 16, 2024

SELL
$71.58 - $87.29 $182,529 - $222,589
-2,550 Reduced 72.86%
950 $70,000
Q1 2024

May 14, 2024

BUY
$71.58 - $87.29 $225,477 - $274,963
3,150 Added 900.0%
3,500 $222,000
Q4 2023

Feb 13, 2024

SELL
$73.27 - $83.09 $40,298 - $45,699
-550 Reduced 61.11%
350 $28,000
Q3 2023

Nov 13, 2023

BUY
$73.94 - $80.67 $66,546 - $72,603
900 New
900 $67,000
Q2 2022

Aug 12, 2022

SELL
$57.72 - $65.01 $59,163 - $66,635
-1,025 Closed
0 $0
Q1 2022

May 10, 2022

BUY
$57.92 - $72.58 $59,368 - $74,394
1,025 New
1,025 $61,000
Q3 2021

Nov 12, 2021

SELL
$67.69 - $73.03 $33,845 - $36,515
-500 Closed
0 $0
Q4 2020

Feb 12, 2021

BUY
$56.65 - $64.55 $28,325 - $32,275
500 New
500 $29,000
Q2 2020

Aug 13, 2020

SELL
$72.34 - $84.0 $9,042 - $10,500
-125 Closed
0 $0
Q1 2020

May 13, 2020

SELL
$62.63 - $80.22 $236,428 - $302,830
-3,775 Reduced 96.79%
125 $9,000
Q4 2019

Feb 14, 2020

BUY
$61.62 - $67.78 $24,648 - $27,112
400 Added 11.43%
3,900 $253,000
Q2 2019

Aug 14, 2019

BUY
$61.87 - $69.38 $216,545 - $242,829
3,500 New
3,500 $236,000
Q3 2018

Nov 13, 2018

SELL
$71.28 - $78.92 $270,864 - $299,896
-3,800 Closed
0 $0
Q2 2018

Aug 14, 2018

BUY
$64.88 - $75.68 $246,543 - $287,584
3,800 New
3,800 $269,000

Others Institutions Holding GILD

About GILEAD SCIENCES, INC.


  • Ticker GILD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,253,369,984
  • Market Cap $111B
  • Description
  • Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...
More about GILD
Track This Portfolio

Track Elkhorn Partners Limited Partnership Portfolio

Follow Elkhorn Partners Limited Partnership and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Elkhorn Partners Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Elkhorn Partners Limited Partnership with notifications on news.